8 Jul 2026
Oral Wegovy vs Injectable Wegovy: Which Should You Choose?
All medical information is reviewed by our clinical partners at MedicOnline.
Dr. Jahan Khan, CMO @ MedicOnline
IMC 409788
The Wegovy pill has been one of the most talked-about developments in weight management since the injectable version launched in Ireland in March 2025. And for good reason. A daily tablet that delivers the same weight loss as a weekly injection is a genuine step forward.
But here is where it gets confusing. The Wegovy pill has been approved in the United States since December 2025. It has not yet been approved in Europe. Irish patients cannot access it through any legitimate channel right now.
So if you are reading this from Ireland, the practical question is not "pill or injection?" It is "should I start on injectable Wegovy now, or wait for the pill?"
This guide sets out the clinical evidence for both formats, explains how they differ in practice, and helps you think through the decision with your doctor. For a full breakdown of the regulatory timeline, see our post on when the Wegovy pill will be available in Ireland.
Same Drug, Different Format
Both the Wegovy injection and the Wegovy pill contain semaglutide. It is the same active ingredient working through the same mechanism - mimicking the GLP-1 hormone to reduce appetite, slow gastric emptying, and help you feel full on less food.
The difference is how it gets into your system. The injection delivers semaglutide directly into the tissue under your skin, once a week. The pill delivers it through your stomach lining, once a day. The body absorbs them differently, which is why the doses look so different - 2.4mg weekly for the injection versus 25mg daily for the pill at maintenance.
What matters to most patients is not the pharmacology. It is whether the results are comparable and whether one is easier to live with than the other.
What the Clinical Trials Show
The injectable Wegovy was studied in the STEP trial programme. The pill was studied in the OASIS trial programme. Both were large, well-designed clinical trials, though they were not run as a direct head-to-head comparison.
Active ingredient
Injection: Semaglutide
Pill: Semaglutide
Maintenance dose
Injection: 2.4mg weekly
Pill: 25mg daily
How it is taken
Injection: Self-injection (prefilled pen)
Pill: Oral tablet
Average weight loss (trials)
Injection: 15-17% of body weight over 68 weeks (STEP 1)
Pill: 15-17% of body weight over 68 weeks (OASIS 1)
Common side effects
Injection: Nausea, diarrhoea, constipation
Pill: Nausea, diarrhoea, constipation (similar profile)
Cardiovascular benefit
Injection: Proven (SELECT trial - 20% MACE reduction)
Pill: Not yet studied in dedicated CV outcome trial
Available in Ireland
Injection: Yes (since March 2025)
Pill: No (pending EMA approval)
The headline finding is that the weight loss results are comparable. The OASIS 1 trial reported average weight loss of 15.1% to 17.4% over 68 weeks with the 50mg pill dose, which essentially matches the results from the STEP programme with the injection. The safety profile is also similar - the most common side effects remain gastrointestinal, and they tend to follow the same pattern of appearing during dose escalation and easing as the body adjusts.
One area where the injection currently has a stronger evidence base is cardiovascular outcomes. The SELECT trial demonstrated that injectable semaglutide reduced the risk of major cardiovascular events by 20% in patients with obesity and existing heart disease. No equivalent trial has been completed for the oral version.
The Practical Differences
Beyond the clinical data, the day-to-day experience of each format differs in ways that matter to real people.
The injection is taken once a week. You choose a day, inject using a prefilled pen (no mixing or preparation), and you are done for seven days. Most patients say the injection itself is quick and painless after the first couple of times. The pen needs to be stored in the fridge before first use.
The pill is taken every day, first thing in the morning on an empty stomach, with a small amount of plain water (no more than 120ml). You then need to wait at least 30 minutes before eating, drinking anything else, or taking other medications. This is because oral semaglutide is absorbed through the stomach lining, and food or other liquids can interfere with that absorption.
For some people, the daily routine of a pill feels more natural than a weekly injection. For others, having to plan their morning around the 30-minute fasting window is less convenient than a once-a-week injection they barely think about.
Neither format is objectively better. It comes down to what fits your life.
The Needle Question
We hear from many patients who are interested in weight loss treatment but anxious about injecting. That is completely valid.
A few things worth knowing. The Wegovy pen uses a very fine needle and an auto-injection mechanism. You press it against your skin and click a button - you do not manually push a syringe. Most patients say it feels like a brief pinch, and many say they do not feel it at all after the first couple of weeks.
If needle anxiety is genuinely the thing holding you back from starting treatment, it is worth weighing up whether waiting 12 to 18 months for a pill that has the same results is in your best interest - particularly if your health would benefit from starting treatment now. That is a conversation for you and your doctor, but it is one worth having honestly.
What About Rybelsus?
If you have seen oral semaglutide mentioned as already available in Ireland, that is Rybelsus. It is a different product. Rybelsus contains a lower dose of semaglutide (up to 14mg) and is licensed for type 2 diabetes management, not for weight management.
Using Rybelsus off-label for weight loss is not recommended. The dose is substantially lower than what has been shown to be effective for weight management in clinical trials, and it is not approved for that purpose. Any website or provider claiming to offer oral semaglutide for weight loss in Ireland right now should be treated with extreme caution.
When Will the Pill Reach Ireland?
The EMA is actively reviewing the oral semaglutide 25mg formulation. Based on typical EMA timelines and Novo Nordisk's own guidance, a realistic window for Irish availability is late 2027 to 2028. This involves EMA approval, followed by HPRA listing and pharmacy distribution.
Novo Nordisk has committed €432 million to upgrade its Athlone facility to manufacture the oral Wegovy pill for markets outside the US - a significant investment that signals confidence in EU approval. But regulatory processes take time, and no approval is guaranteed.
For the most current status, we keep our Wegovy pill availability post updated as developments happen.
So What Should You Do Right Now?
If you are eligible for treatment and your health would benefit from starting, the injectable Wegovy is available, proven, and working for thousands of Irish patients today.
The evidence behind it is extensive. The clinical results are strong. And waiting 12 to 18 months for a pill that delivers the same results, when an equally effective treatment exists right now, is rarely in a patient's best interest - medically or practically.
That said, we understand that needle anxiety is a real barrier for some people. If the injection has been the only thing stopping you from starting, stay informed about the pill timeline and have an honest conversation with a doctor about your options. There may be more to discuss than you think.
A prescription is not guaranteed. Eligibility for Wegovy is determined by an IMC-registered doctor based on your BMI, medical history, and overall health profile. If you would like to find out whether you qualify, you can complete our online assessment in under 4 minutes. If you are not eligible, you receive a full refund.
Not sure where your BMI sits? Use our BMI calculator to get a quick estimate before you start.
Am I eligible for weight loss treatment?
Calculate your BMI to see where your weight loss journey could take you
References
- Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 384(11), 989-1002.
- Knop, F. K., et al. (2023). Oral Semaglutide 50mg Taken Once Daily in Adults with Overweight or Obesity (OASIS 1). The Lancet, 402(10403), 705-719.
- Lincoff, A. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine, 389(24), 2221-2232.
- European Medicines Agency (EMA). Wegovy (Semaglutide): EPAR.
Related Blogs
Who Qualifies for Mounjaro in Ireland?
An overview of the clinical criteria, safety checks, and medical assessment process doctors use to decide who is eligible for Mounjaro® (tirzepatide) in Ireland.
Read
What weight loss injections are available in Ireland?
A clear breakdown of the three main medical treatments for weight management in Ireland in 2025 and 2026
Read
Who can't take Mounjaro? Understanding the contraindications
A comprehensive guide to the absolute contraindications and other cautions that determine who cannot safely take Mounjaro® (tirzepatide) in Ireland.
ReadWho Qualifies for Mounjaro in Ireland?
An overview of the clinical criteria, safety checks, and medical assessment process doctors use to decide who is eligible for Mounjaro® (tirzepatide) in Ireland.
What weight loss injections are available in Ireland?
A clear breakdown of the three main medical treatments for weight management in Ireland in 2025 and 2026
Who can't take Mounjaro? Understanding the contraindications
A comprehensive guide to the absolute contraindications and other cautions that determine who cannot safely take Mounjaro® (tirzepatide) in Ireland.